MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.28
+0.07
+1.34%
Opening 09:38 04/02 EDT
OPEN
5.14
PREV CLOSE
5.21
HIGH
5.28
LOW
5.14
VOLUME
1.60K
TURNOVER
--
52 WEEK HIGH
11.93
52 WEEK LOW
4.260
MARKET CAP
229.14M
P/E (TTM)
-2.8078
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SYRS stock price target is 12.17 with a high estimate of 17.00 and a low estimate of 8.00.

EPS

SYRS News

More
  • Edited Transcript of SYRS earnings conference call or presentation 5-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/26 08:25
  • Does Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Have A High Beta?
  • Simply Wall St. · 03/22 15:27
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • H.C. Wainwright Reiterates Neutral on Syros Pharmaceuticals, Lowers Price Target to $8
  • Benzinga · 03/06 13:09

Industry

Pharmaceuticals
+0.03%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Symbol
Price
%Change

About SYRS

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
More

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.